biostudies-literatureMueller BUNCRR NIH HHS259-62https://www.ebi.ac.uk/biostudies/studies/S-EPMC5752113biostudies-literatureUnknown52(2)<h4>Background</h4>We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.<h4>Methods</h4>Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.<h4>Results</h4>Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention.<h4>Conclusions</h4>Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%).Pediatric blood & cancerOne year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.PMC5752113M01RR000188M01 RR000070M01RR002172M01-RR0000047M01 RR000865M01 RR000047M01 RR002172M01 RR000188M01RR-001271M01 RR001271M01RR000865Abshire TCMoore TBBussel JBLoh MLBennett CMBuchanan GRGlaser Pediatric Research NetworkMueller BULorenzana ANNeufeld EJGlader BEOlson TASawaf HMahoney DHFeig SAPediatric Rituximab/ITP Study GroupRogers ZRFeldman HAMcCarthy MCMentzer WCfalseOne year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.<h4>Background</h4>We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.<h4>Methods</h4>Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.<h4>Results</h4>Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention.<h4>Conclusions</h4>Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%).2009-01-01T00:00:00Z2009 Feb2025-04-22T21:41:36.688Z2019-03-27T03:06:14ZS-EPMC57521131893733310.1002/pbc.21757